Az IMPROVEMENT HF európai felmérés magyar eredményei a szívelégtelenség korszeru diagnosztikájának és kezelésének mindennapi gyakorlatáról: Az európai és hazai adatok összehasonlítása

Translated title of the contribution: Hungarian results of the IMPROVEMENT HF European survey on the everyday diagnostics and treatment of heart failure: Comparison of European and Hungarian data

I. Préda, J. G F Cleland, Juan Cosin-Aguilar, Alain Cohen-Solal, Rainer Dietz, Ferenc Follath, Nick Freemantel, Antonello Gavazzi, Richard Hobbs, Jerzy Korewicki, Hugo Madeira, Karl Swedberg, Wiek Van Gilst, Jiri Widimsky

Research output: Contribution to journalArticle

Abstract

The Working Group on Heart Failure of the European Society of Cardiology published guidelines on diagnosis and treatment of heart failure in 1995, 1997 and 2001. The IMPROVEMENT HF Study, examining a set of data obtained by 1363 family care physicians and 11.062 patients suffering in (or suspected of) heart failure, was primarily focused on a survey of the perception of the diagnostic signs and symptoms of heart failure and the real treatment of the patients suffering in heart failure. Hungary participated in the study with 98 familiy care physicians in 12 investigation centers. The mean age of the European patients was 70± 12 years, which was 66± 10 years in the cases of the Hungarian participants. The Hungarian patients had hypertension (60%), diabetes mellitus (28%) and previous myocardial infarction (40%), exceeding thus in all aspects the European mean values of the cohort. Both ECG and echocardiographic diagnostic examinations were extensively used in Hungary in diagnosing heart failure, and the recognition of diastolic and systolic left ventricular dysfunction signs is one of the best in Europe. Similarly, the functional classes of heart failure based on the New York Heart Accociation classification is also well known among the family practitioners in Hungary. The modern trends in the treatment of chronic heart failure, with a special regard to the angiotensine convertase enzyme inhibitors and beta receptor blockers were also wide spread during the study period (1999-2001) in Hungary. In spite of that, the mean daily therapeutic dose of angiotensine convertase enzyme blockers did not reach the required dose, only prindopril, bearing a long lasting therapeutic plasma level, approached the daily target dose. It is a special succes, that the Hungarian incidence of the combined angiotensine convertase inhibitor and beta receptor blokker therapy was the highest (44%) among the European countries. The International Study Group on Heart Failure of the Working Group of the European Society of Cardiology considers that the individual differences in perception and also in treatment in the European countries may be the consequence of the differtent structures in medical education and postgraduate teaching, and also of the differences in health care expenses. However, differences in the organization of health care may also be important.

Original languageHungarian
Pages (from-to)23-33
Number of pages11
JournalOrvoskepzes
Volume78
Issue number1
Publication statusPublished - 2003

Fingerprint

Treatment Failure
Heart Failure
Hungary
Therapeutics
Diastolic Heart Failure
Systolic Heart Failure
Delivery of Health Care
Surveys and Questionnaires
Family Physicians
Left Ventricular Dysfunction
Enzyme Inhibitors
Medical Education
Individuality
Signs and Symptoms
Diabetes Mellitus
Teaching
Electrocardiography
Myocardial Infarction
Organizations
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az IMPROVEMENT HF európai felmérés magyar eredményei a szívelégtelenség korszeru diagnosztikájának és kezelésének mindennapi gyakorlatáról : Az európai és hazai adatok összehasonlítása. / Préda, I.; Cleland, J. G F; Cosin-Aguilar, Juan; Cohen-Solal, Alain; Dietz, Rainer; Follath, Ferenc; Freemantel, Nick; Gavazzi, Antonello; Hobbs, Richard; Korewicki, Jerzy; Madeira, Hugo; Swedberg, Karl; Van Gilst, Wiek; Widimsky, Jiri.

In: Orvoskepzes, Vol. 78, No. 1, 2003, p. 23-33.

Research output: Contribution to journalArticle

Préda, I, Cleland, JGF, Cosin-Aguilar, J, Cohen-Solal, A, Dietz, R, Follath, F, Freemantel, N, Gavazzi, A, Hobbs, R, Korewicki, J, Madeira, H, Swedberg, K, Van Gilst, W & Widimsky, J 2003, 'Az IMPROVEMENT HF európai felmérés magyar eredményei a szívelégtelenség korszeru diagnosztikájának és kezelésének mindennapi gyakorlatáról: Az európai és hazai adatok összehasonlítása', Orvoskepzes, vol. 78, no. 1, pp. 23-33.
Préda, I. ; Cleland, J. G F ; Cosin-Aguilar, Juan ; Cohen-Solal, Alain ; Dietz, Rainer ; Follath, Ferenc ; Freemantel, Nick ; Gavazzi, Antonello ; Hobbs, Richard ; Korewicki, Jerzy ; Madeira, Hugo ; Swedberg, Karl ; Van Gilst, Wiek ; Widimsky, Jiri. / Az IMPROVEMENT HF európai felmérés magyar eredményei a szívelégtelenség korszeru diagnosztikájának és kezelésének mindennapi gyakorlatáról : Az európai és hazai adatok összehasonlítása. In: Orvoskepzes. 2003 ; Vol. 78, No. 1. pp. 23-33.
@article{b26df249a00f41058321019140263d05,
title = "Az IMPROVEMENT HF eur{\'o}pai felm{\'e}r{\'e}s magyar eredm{\'e}nyei a sz{\'i}vel{\'e}gtelens{\'e}g korszeru diagnosztik{\'a}j{\'a}nak {\'e}s kezel{\'e}s{\'e}nek mindennapi gyakorlat{\'a}r{\'o}l: Az eur{\'o}pai {\'e}s hazai adatok {\"o}sszehasonl{\'i}t{\'a}sa",
abstract = "The Working Group on Heart Failure of the European Society of Cardiology published guidelines on diagnosis and treatment of heart failure in 1995, 1997 and 2001. The IMPROVEMENT HF Study, examining a set of data obtained by 1363 family care physicians and 11.062 patients suffering in (or suspected of) heart failure, was primarily focused on a survey of the perception of the diagnostic signs and symptoms of heart failure and the real treatment of the patients suffering in heart failure. Hungary participated in the study with 98 familiy care physicians in 12 investigation centers. The mean age of the European patients was 70± 12 years, which was 66± 10 years in the cases of the Hungarian participants. The Hungarian patients had hypertension (60{\%}), diabetes mellitus (28{\%}) and previous myocardial infarction (40{\%}), exceeding thus in all aspects the European mean values of the cohort. Both ECG and echocardiographic diagnostic examinations were extensively used in Hungary in diagnosing heart failure, and the recognition of diastolic and systolic left ventricular dysfunction signs is one of the best in Europe. Similarly, the functional classes of heart failure based on the New York Heart Accociation classification is also well known among the family practitioners in Hungary. The modern trends in the treatment of chronic heart failure, with a special regard to the angiotensine convertase enzyme inhibitors and beta receptor blockers were also wide spread during the study period (1999-2001) in Hungary. In spite of that, the mean daily therapeutic dose of angiotensine convertase enzyme blockers did not reach the required dose, only prindopril, bearing a long lasting therapeutic plasma level, approached the daily target dose. It is a special succes, that the Hungarian incidence of the combined angiotensine convertase inhibitor and beta receptor blokker therapy was the highest (44{\%}) among the European countries. The International Study Group on Heart Failure of the Working Group of the European Society of Cardiology considers that the individual differences in perception and also in treatment in the European countries may be the consequence of the differtent structures in medical education and postgraduate teaching, and also of the differences in health care expenses. However, differences in the organization of health care may also be important.",
keywords = "ACE inhibitors, Beta receptor blockers, European survay, Heart failure, Myocardial inferction, Population data",
author = "I. Pr{\'e}da and Cleland, {J. G F} and Juan Cosin-Aguilar and Alain Cohen-Solal and Rainer Dietz and Ferenc Follath and Nick Freemantel and Antonello Gavazzi and Richard Hobbs and Jerzy Korewicki and Hugo Madeira and Karl Swedberg and {Van Gilst}, Wiek and Jiri Widimsky",
year = "2003",
language = "Hungarian",
volume = "78",
pages = "23--33",
journal = "Orvoskepzes",
issn = "0030-6037",
publisher = "Semmelweis Kiado",
number = "1",

}

TY - JOUR

T1 - Az IMPROVEMENT HF európai felmérés magyar eredményei a szívelégtelenség korszeru diagnosztikájának és kezelésének mindennapi gyakorlatáról

T2 - Az európai és hazai adatok összehasonlítása

AU - Préda, I.

AU - Cleland, J. G F

AU - Cosin-Aguilar, Juan

AU - Cohen-Solal, Alain

AU - Dietz, Rainer

AU - Follath, Ferenc

AU - Freemantel, Nick

AU - Gavazzi, Antonello

AU - Hobbs, Richard

AU - Korewicki, Jerzy

AU - Madeira, Hugo

AU - Swedberg, Karl

AU - Van Gilst, Wiek

AU - Widimsky, Jiri

PY - 2003

Y1 - 2003

N2 - The Working Group on Heart Failure of the European Society of Cardiology published guidelines on diagnosis and treatment of heart failure in 1995, 1997 and 2001. The IMPROVEMENT HF Study, examining a set of data obtained by 1363 family care physicians and 11.062 patients suffering in (or suspected of) heart failure, was primarily focused on a survey of the perception of the diagnostic signs and symptoms of heart failure and the real treatment of the patients suffering in heart failure. Hungary participated in the study with 98 familiy care physicians in 12 investigation centers. The mean age of the European patients was 70± 12 years, which was 66± 10 years in the cases of the Hungarian participants. The Hungarian patients had hypertension (60%), diabetes mellitus (28%) and previous myocardial infarction (40%), exceeding thus in all aspects the European mean values of the cohort. Both ECG and echocardiographic diagnostic examinations were extensively used in Hungary in diagnosing heart failure, and the recognition of diastolic and systolic left ventricular dysfunction signs is one of the best in Europe. Similarly, the functional classes of heart failure based on the New York Heart Accociation classification is also well known among the family practitioners in Hungary. The modern trends in the treatment of chronic heart failure, with a special regard to the angiotensine convertase enzyme inhibitors and beta receptor blockers were also wide spread during the study period (1999-2001) in Hungary. In spite of that, the mean daily therapeutic dose of angiotensine convertase enzyme blockers did not reach the required dose, only prindopril, bearing a long lasting therapeutic plasma level, approached the daily target dose. It is a special succes, that the Hungarian incidence of the combined angiotensine convertase inhibitor and beta receptor blokker therapy was the highest (44%) among the European countries. The International Study Group on Heart Failure of the Working Group of the European Society of Cardiology considers that the individual differences in perception and also in treatment in the European countries may be the consequence of the differtent structures in medical education and postgraduate teaching, and also of the differences in health care expenses. However, differences in the organization of health care may also be important.

AB - The Working Group on Heart Failure of the European Society of Cardiology published guidelines on diagnosis and treatment of heart failure in 1995, 1997 and 2001. The IMPROVEMENT HF Study, examining a set of data obtained by 1363 family care physicians and 11.062 patients suffering in (or suspected of) heart failure, was primarily focused on a survey of the perception of the diagnostic signs and symptoms of heart failure and the real treatment of the patients suffering in heart failure. Hungary participated in the study with 98 familiy care physicians in 12 investigation centers. The mean age of the European patients was 70± 12 years, which was 66± 10 years in the cases of the Hungarian participants. The Hungarian patients had hypertension (60%), diabetes mellitus (28%) and previous myocardial infarction (40%), exceeding thus in all aspects the European mean values of the cohort. Both ECG and echocardiographic diagnostic examinations were extensively used in Hungary in diagnosing heart failure, and the recognition of diastolic and systolic left ventricular dysfunction signs is one of the best in Europe. Similarly, the functional classes of heart failure based on the New York Heart Accociation classification is also well known among the family practitioners in Hungary. The modern trends in the treatment of chronic heart failure, with a special regard to the angiotensine convertase enzyme inhibitors and beta receptor blockers were also wide spread during the study period (1999-2001) in Hungary. In spite of that, the mean daily therapeutic dose of angiotensine convertase enzyme blockers did not reach the required dose, only prindopril, bearing a long lasting therapeutic plasma level, approached the daily target dose. It is a special succes, that the Hungarian incidence of the combined angiotensine convertase inhibitor and beta receptor blokker therapy was the highest (44%) among the European countries. The International Study Group on Heart Failure of the Working Group of the European Society of Cardiology considers that the individual differences in perception and also in treatment in the European countries may be the consequence of the differtent structures in medical education and postgraduate teaching, and also of the differences in health care expenses. However, differences in the organization of health care may also be important.

KW - ACE inhibitors

KW - Beta receptor blockers

KW - European survay

KW - Heart failure

KW - Myocardial inferction

KW - Population data

UR - http://www.scopus.com/inward/record.url?scp=38549166598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549166598&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:38549166598

VL - 78

SP - 23

EP - 33

JO - Orvoskepzes

JF - Orvoskepzes

SN - 0030-6037

IS - 1

ER -